Negative symptoms in schizophrenia: comments from a clinical psychology perspective

Schizophrenia Bulletin

Volumn 32, Issue 2, 2006, Pages 231-233

  Tarrier, Nicholas ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical psychology; Negative symptoms; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

BEHAVIOR THERAPY; CLINICAL PRACTICE; CLINICAL PSYCHOLOGY; COGNITIVE THERAPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CONSTRUCT VALIDITY; DEPRESSION; FOLLOW UP; HUMAN; HYPOTHESIS; LONGITUDINAL STUDY; MENTAL HEALTH CARE; METHODOLOGY; MODEL; NEGATIVE SYNDROME; NEUROBIOLOGY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL CARE; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL ENVIRONMENT; SYMPTOM;

HUMANS; PSYCHOLOGY, CLINICAL; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 33645238559     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbj051     Document Type: Conference Paper

References (10)

1. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: I. meta-analysis of family intervention and cognitive behavior therapy. Psychol Med. 2002;32:763-782.
2. National Institute for Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: National Health Service, National Institute for Clinical Excellence; 2002. http://www.nice.org./pdf/CG1NICEguideline.pdf (accessed 19 Jan 2006).
3. Moncrieff J, Hopker S, Thomas P. Psychiatry and the pharmaceutical industry: who pays the piper? Psychiatr Bull. 2005;29:84-86.
4. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. New Engl J Med. 2000;342:1539-1544.
5. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br Med J. 2003;326:1167-1170.
6. Tarrier N, Barrowclough C, Haddock G, McGovern J. The dissemination of innovative cognitive-behavioural treatments for schizophrenia. J Ment Health. 1999;8:569-582.
7. Haddock G, Barrowclough C, Tarrier N, et al. Randomised controlled trial of cognitive-behaviour therapy and motivational intervention for schizophrenia and substance use: 18 month, carer, and economic outcomes. Br J Psychiatry. 2003;183:418-426.
8. Tarrier N, Kinney C, McCarthy E, Humphreys L, Wittkowski A, Morris J. Two-year follow-up of cognitive-behavior therapy and supportive counseling in the treatment of persistent positive symptoms in chronic schizophrenia. J Consult Clin Psychol. 2000;68:917-922.
9. Remington G, Chong S-A, Kapur S. Distinguishing changes in primary and secondary negative symptoms. Am J Psychiatry. 1999;156:974-975.
10. Selten JP, Gernaat HB, Nolen WA, Wiersma D, van den Bosch RJ. Experience of negative symptoms: comparison of schizophrenic patients to patients with a depressive disorder and to normal subjects. Am J Psychiatry. 1998;155:350-354.